SWM
VYNE icon

Spire Wealth Management’s VYNE Therapeutics VYNE Stock Holding History

Spire Wealth Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-109
Closed -$2K – 2897
2021
Q4 		$2K Buy
+109
New +$2.34K ﹤0.01% 2815
2021
Q2 		– Sell
-949
Closed -$117K – 2987
2021
Q1 		$117K Buy
+949
New +$138K ﹤0.01% 1332

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

Spire Wealth Management's VYNE Position: Q1 2022 in Review

Spire Wealth Management sold out of VYNE Therapeutics (VYNE) in Q1 2022, closing a stake of 109 shares — an estimated $2K sold.

Spire Wealth Management first reported a position in VYNE in Q1 2021 and held it in 2 quarters. The position peaked at $117K in Q1 2021. 44 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

  • Spire Wealth Management reported no remaining VYNE Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 109 VYNE Therapeutics shares in Q1 2022, an estimated $2K.
  • Spire Wealth Management first reported a position in VYNE Therapeutics in Q1 2021 and held it in 2 quarters.
  • Spire Wealth Management's VYNE Therapeutics position peaked at $117K in Q1 2021.
  • 44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.